Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | ARCHES post-hoc analyses: efficacy of ENZA + ADT in mHSPC by pattern of metastatic spread

Neal Shore, MD, Carolina Urologic Research Center, Myrtle Beach, SC, discusses the post-hoc analyses of the ARCHES trial (NCT02677896), which investigated androgen deprivation therapy (ADT) with enzalutamide (ENZA) or a placebo in metastatic hormone-sensitive prostate cancer (mHSPC). The post-hoc analyses assessed how the pattern of metastatic spread impacts the efficacy of ENZA + ADT in mHSPC patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.